PetVivo (PETV) investor relations material

Company overview and product innovation

• Operates four subsidiaries, including animal health, AI, human health, and manufacturing arms.

• Flagship products include Spryng with OsteoCushion Technology and PrecisePRP, both targeting joint health in animals.

• AI platform launching within 45–60 days aims to improve communication and efficiency in veterinary clinics.

• Manufacturing facility holds ISO 5, 7, and 8 certifications, exceeding animal health requirements.

• Deep patent portfolio and trade secrets protect technology and future product pipeline.

Market opportunity and expansion

• Targets the $40 billion U.S. animal health veterinary market, growing over 5% annually.

• U.S. commercialization since 2021, with expansion into the U.K., Mexico, and Canada.

• Top five U.S. distributors cover 95% of veterinary clinics; international growth ongoing.

• Pet insurance market growth supports reimbursement for veterinary medical devices.

• Demographic trends show increased pet spending, especially among Gen Z and Millennials.

Clinical results and product differentiation

• Spryng mimics cartilage, lasts about 12 months per injection, and reduces need for pharmaceuticals.

• Human trials as dermal filler showed strong results versus Restylane; over 12,000 animals treated.

• PrecisePRP offers off-the-shelf PRP without blood draw, saving time and improving consistency.

• Studies show superior outcomes in hip dysplasia and CCL ruptures compared to gold standards.

• Ongoing and upcoming studies with leading veterinary researchers and institutions.